within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA18_Pazufloxacin;

model Pazufloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.0305555555555553e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0156,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.008400000000000001,
    k12 = 3.111111111111111e-06,
    k21 = 3.111111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pazufloxacin</td></tr><tr><td>ATC code:</td><td>J01MA18</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>15.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.31</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pazufloxacin is a fluoroquinolone antibiotic, primarily used for the treatment of bacterial infections such as respiratory tract infections, urinary tract infections, and intra-abdominal infections. It is mainly used in Japan and some other Asian countries and is not widely approved in the US or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult male volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>Lee, J, et al., &amp; Yoon, YR (2012). Single-dose pharmacokinetics and dose proportionality of intravenous pazufloxacin mesilate in healthy Korean volunteers. <i>Expert opinion on drug metabolism &amp; toxicology</i> 8(8) 921–928. DOI:<a href=\"https://doi.org/10.1517/17425255.2012.688951\">10.1517/17425255.2012.688951</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22809012/\">https://pubmed.ncbi.nlm.nih.gov/22809012</a></p></li><li><p>Oonishi, Y, et al., &amp; Yamaguchi, K (2007). Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. <i>The Journal of antimicrobial chemotherapy</i> 60(5) 1030–1037. DOI:<a href=\"https://doi.org/10.1093/jac/dkm344\">10.1093/jac/dkm344</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17827137/\">https://pubmed.ncbi.nlm.nih.gov/17827137</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01MA18 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pazufloxacin;
